Business Wire

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.

Share

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.

In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption.

About PL BioScience:

Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases; from standard laboratory research to GMP cell therapies. From academic research, pre-clinical research, and cell therapy, the high quality GMP compliant standards of ELAREM™ ensures seamless transitions of regenerative medicine breakthroughs – from the lab to patients in need.

About Macopharma

Founded in 1977, Macopharma is a major player in the medical devices industry in the blood sector. Based in Tourcoing, in the North of France (59), its development has always been driven by important innovations, results of investments made in research and development and collaborations customers and partners (blood transfusion centers, research laboratories, hospitals...). For all these activities, Macopharma offers a range of solutions that respond to each step of the process from donor to patient.

With more than 2000 employees, 3 plants (in France, Poland and Tunisia) and a presence in nearly 100 countries worldwide, Macopharma's vision is to provide sustainable products and integrated services to ensure safe and secured blood component solutions to every patient in the world.

For more information, visit macopharma.com and follow Linkedin MACOPHARMA

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Hatim Hemeda
PL BioScience GmbH
+49(0)24195719-100
info@pl-bioscience.com

+33(0)320118-400
Contact@macopharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches First-of-Its-Kind, Easy-to-Install Methane Measurement Instrument4.10.2023 04:00:00 CEST | Press release

SLB’s End-to-end Emissions Solutions (SEES) business today introduced its next generation methane point instrument, a self-installed continuous methane monitoring system that uses IoT-enabled sensors to quickly and cost effectively detect, locate and quantify emissions across oil and gas operations. Effective monitoring is essential to reduce emissions of methane, a greenhouse gas (GHG) which has a climate change impact up to 84 times greater than carbon dioxide over a 20-year timescale and represents about half of the oil and gas sector’s operational emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003896530/en/ The compact, self-install device for continuous methane monitoring enables fast, affordable deployment at any scale. (Photo: Business Wire) The methane point instrument represents a step change in methane measurement technology, providing operators with industry-leading leak detection sensitivity in a sm

"HD-PLC Alliance" is renamed "Nessum Alliance" as it enters a New Era of Wired and Wireless (Any Media) IoT Communication Applications!4.10.2023 03:00:00 CEST | Press release

HD-PLC*1 Alliance announced that it has changed its name from "HD-PLC Alliance" to "Nessum*2 Alliance" (hereinafter referred to as "Alliance") to promote the next generations of IEEE 1901*3 standards for wired and wireless (Any Media) communication for the Industrial IoT market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003535815/en/ Society and Lifestyles with Nessum (Graphic: Business Wire) As a background to this change of name to "Nessum Alliance", after Panasonic's communication technology based on the Wavelet OFDM PHY/MAC technology*4 was approved as Draft 1.0 in the working group in August for the next-generation communication standard IEEE P1901c*5 of the IEEE Standards Association which the Alliance and its members participate in, Panasonic changed the brand name of the communication technology "HD-PLC" to "Nessum" last month*6. In response to this, the Alliance has changed its organization name in order to

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years3.10.2023 22:50:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK)today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). In the coming months, the WHO will consider the SAGE recommendation and update its position paper on dengue vaccines to include final guidance on the use of QDENGA in public vaccination programs. SAGE made the following recommendations: The vaccine to be considered for introduction in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons. The vaccine to be introduced to children aged 6 to 16 years of age. Within this age range, the vaccine should be introduced about 1-2 years prior to the age-specific peak incidence of dengue-related hospitalizations. The vaccine should be administered in a 2-dose schedule with a 3-month interval betw

Verimatrix To Showcase Cybersecurity Solutions at GovWare 20233.10.2023 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its Extended Threat Defense (XTD) technologies at GovWare 2023 taking place October 17-19 at Singapore’s Sands Expo and Convention Centre. Located in GovWare booth C19, Verimatrix will offer hands-on demonstrations as well as customer success stories for its portfolio of award-winning XTD cybersecurity solutions that enable mobile app developers to harness the latest protections against hackers seeking to use mobile apps and websites as tools to attack enterprises. GovWare 2023 promises yet another invigorating event where knowledge, ideas, insights and technologies will be shared among cybersecurity leaders and innovators. Under the theme “Fostering Trust Through Collaboration in the New Digital Reality,” GovWare 2023, a part of the renowned Singapore International Cyber Week (SICW), is set to deliver transformative insi

Evolve Additive Solutions Announces Strategic Partnership with alphacam to Provide STEP Parts Production in Europe3.10.2023 16:00:00 CEST | Press release

Evolve Additive Solutions, provider of industrial 3D printing solutions and inventor of the transformative Selective Thermoplastic Electrophotographic Process (STEP), announces a strategic partnership with alphacam GmbH to offer STEP-manufactured parts as a service to customers throughout Europe. STEP is a groundbreaking additive manufacturing technology that addresses the manufacturing constraints in accuracy, scalability and engineering-grade materials by other technologies in market today. alphacam will combine its deep industry expertise, vast experience in printing plastic parts, and strong customer relationships with its adoption of Evolve’s Scaled Volume Production (SVP) platform to produce and deliver fully dense, high-fidelity thermoplastic parts with near injection molding surface finish and properties. This marks the 2nd partnership of this kind introduced by Evolve as part of its mission to establish STEP production centers of excellence around the world – ultimately to inc